The high efficacy of GSK461364 alone may suggest its applicability (or that of equivalent PLK1 inhibitors) in mono-therapy for treatment of CD37-targeting RIT-resistant DLBCL or aggressive ABC-DLBCL. This evidence concerns the gene PLK1 and diffuse large B-cell lymphoma.